This inventor holds 6 USPTO granted patents. Top assignees: Fournier Innovation Et Synergie, Institut De Recherches Chimiques Et Al, Institut De Recherches Chimiques Et Bioloques Appliquees Irceba. Active years: 1989-2011.
Company Filing History:
1 out of 7 
1 out of 1 
1 out of 1 Years Active: 1989-2011
Title: Philippe Reginault: Pioneering Innovator in Pharmaceutical Formulations
Introduction:
Philippe Reginault, a resident of Fontaine les Dijon, France, is a brilliant inventor and a key contributor to the pharmaceutical industry. With a significant number of patents to his name, Reginault has made notable contributions to the field of medication formulations and treatments for various medical conditions. This article delves into Reginault's achievements, his latest patents, career highlights, notable collaborations, and the impact of his work on the industry.
Latest Patents:
Reginault's latest patents demonstrate his expertise in developing groundbreaking pharmaceutical solutions. Two remarkable examples of his innovations are outlined below:
1. Fenofibrate Tablets:
In his most recent patent, Reginault introduces a novel galenic formulation of fenofibrate for oral administration. The invention focuses on the preparation process of fenofibrate tablets by compressing a specific mixture. This innovative formulation not only enhances the oral delivery of fenofibrate but also improves its efficacy, ensuring its optimum therapeutic effects.
2. Treatment of Acute Urinary Retention:
Another groundbreaking invention by Reginault is a composition and method for the treatment of acute urinary retention. This patent introduces a solution where deacetyl moxisylyte or its non-toxic salts are administered through a ready-to-use aqueous solution via the intravenous route. This treatment effectively induces a decrease in urethral contractility, offering relief to patients suffering from acute urinary retention.
Career Highlights:
Reginault's career boasts a remarkable track record of achievements. He has made significant contributions while working with renowned pharmaceutical organizations, including Fournier Innovation et Synergie and Laboratoires Fournier SA. Reginault's exemplary work has earned him recognition and respect within the industry, solidifying his position as a leading innovator.
Collaborations:
Philippe Reginault has collaborated with several esteemed professionals throughout his career, including Eric Teillaud and Alain Guillemet. These collaborations have been instrumental in pushing the boundaries of innovation, fostering an environment of knowledge exchange, and facilitating the development of groundbreaking inventions.
Conclusion:
Philippe Reginault's remarkable contributions to the pharmaceutical industry, demonstrated through his numerous patents and innovative formulations, make him a prominent figure in the field of medication development. His expertise in drug formulation and treatments has paved the way for improved therapeutic interventions and has undoubtedly enhanced patient outcomes. Reginault's collaborations with esteemed colleagues further highlight his commitment to advancing the industry through collective knowledge and expertise. As an exceptional innovator, Reginault continues to leave a lasting impact on the pharmaceutical landscape, inspiring future generations of inventors to push the boundaries of medical science.